Vanguard Group Inc Erasca, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,288,740 shares of ERAS stock, worth $35.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,288,740
Previous 10,351,746
28.37%
Holding current value
$35.1 Million
Previous $24.4 Million
48.5%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ERAS
# of Institutions
141Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$51.2 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$44.4 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$42.8 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$36.3 Million1.48% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$29.2 Million18.15% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $322M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...